Literature DB >> 22088831

Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial.

Esther M Stoop1, Margriet C de Haan, Thomas R de Wijkerslooth, Patrick M Bossuyt, Marjolein van Ballegooijen, C Yung Nio, Marc J van de Vijver, Katharina Biermann, Maarten Thomeer, Monique E van Leerdam, Paul Fockens, Jaap Stoker, Ernst J Kuipers, Evelien Dekker.   

Abstract

BACKGROUND: Screening for colorectal cancer is widely recommended, but the preferred strategy remains unidentified. We aimed to compare participation and diagnostic yield between screening with colonoscopy and with non-cathartic CT colonography.
METHODS: Members of the general population, aged 50-75 years, and living in the regions of Amsterdam or Rotterdam, identified via the registries of the regional municipal administration, were randomly allocated (2:1) to be invited for primary screening for colorectal cancer by colonoscopy or by CT colonography. Randomisation was done per household with a minimisation algorithm based on age, sex, and socioeconomic status. Invitations were sent between June 8, 2009, and Aug 16, 2010. Participants assigned to CT colonography who were found to have one or more large lesions (≥10 mm) were offered colonoscopy; those with 6-9 mm lesions were offered surveillance CT colonography. The primary outcome was the participation rate, defined as number of invitees undergoing the examination relative to the total number of invitees. Diagnostic yield was calculated as number of participants with advanced neoplasia relative to the total number of invitees. Invitees and screening centre employees were not masked to allocation. This trial is registered in the Dutch trial register, number NTR1829.
FINDINGS: 1276 (22%) of 5924 colonoscopy invitees participated, compared with 982 (34%) of 2920 CT colonography invitees (relative risk [RR] 1·56, 95% CI 1·46-1·68; p<0·0001). Of the participants in the colonoscopy group, 111 (9%) had advanced neoplasia of whom seven (<1%) had a carcinoma. Of CT colonography participants, 84 (9%) were offered colonoscopy, of whom 60 (6%) had advanced neoplasia of whom five (<1%) had a carcinoma; 82 (8%) were offered surveillance. The diagnostic yield for all advanced neoplasia was 8·7 per 100 participants for colonoscopy versus 6·1 per 100 for CT colonography (RR 1·46, 95% CI 1·06-2·03; p=0·02) and 1·9 per 100 invitees for colonoscopy and 2·1 per 100 invitees for CT colonography (RR 0·91, 0·66-2·03; p=0·56). The diagnostic yield for advanced neoplasia of 10 mm or more was 1·5 per 100 invitees for colonoscopy and 2·0 per 100 invitees for CT colonography, respectively (RR 0·74, 95% CI 0·53-1·03; p=0·07). Serious adverse events related to the screening procedure were post-polypectomy bleedings: two in the colonoscopy group and three in the CT colonography group.
INTERPRETATION: Participation in colorectal cancer screening with CT colonography was significantly better than with colonoscopy, but colonoscopy identified significantly more advanced neoplasia per 100 participants than did CT colonography. The diagnostic yield for advanced neoplasia per 100 invitees was similar for both strategies, indicating that both techniques can be used for population-based screening for colorectal cancer. Other factors such as cost-effectiveness and perceived burden should be taken into account when deciding which technique is preferable. FUNDING: Netherlands Organisation for Health Research and Development, Centre for Translational Molecular Medicine, and the Nuts Ohra Foundation.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22088831     DOI: 10.1016/S1470-2045(11)70283-2

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  114 in total

1.  Diagnostic imaging: A new dawn for CT scans in colon screening?

Authors:  Rebecca Kirk
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-12-13       Impact factor: 46.802

2.  Gastrointestinal cancer: a new dawn for CT scans in colon screening?

Authors:  Rebecca Kirk
Journal:  Nat Rev Clin Oncol       Date:  2011-11-29       Impact factor: 66.675

3.  Gastrointestinal cancer: Should colonoscopy be a primary test in CRC screening?

Authors:  Evelien Dekker
Journal:  Nat Rev Clin Oncol       Date:  2012-04-10       Impact factor: 66.675

4.  Assessment of an electronic learning system for colon capsule endoscopy: a pilot study.

Authors:  Hirotsugu Watabe; Tetsuya Nakamura; Atsuo Yamada; Yasuo Kakugawa; Sadaharu Nouda; Akira Terano
Journal:  J Gastroenterol       Date:  2015-11-02       Impact factor: 7.527

5.  Colorectal cancer: Strategies to minimize interval CRC in screening programmes.

Authors:  Evelien Dekker; Silvia Sanduleanu
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-01       Impact factor: 46.802

Review 6.  Colorectal cancer screening--optimizing current strategies and new directions.

Authors:  Ernst J Kuipers; Thomas Rösch; Michael Bretthauer
Journal:  Nat Rev Clin Oncol       Date:  2013-02-05       Impact factor: 66.675

Review 7.  Perforation rate in CT colonography: a systematic review of the literature and meta-analysis.

Authors:  Davide Bellini; Marco Rengo; Carlo Nicola De Cecco; Franco Iafrate; Cesare Hassan; Andrea Laghi
Journal:  Eur Radiol       Date:  2014-05-10       Impact factor: 5.315

Review 8.  Computed tomography colonography in 2014: an update on technique and indications.

Authors:  Andrea Laghi
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 9.  CT colonography for population screening: ready for prime time?

Authors:  Perry J Pickhardt
Journal:  Dig Dis Sci       Date:  2014-12-10       Impact factor: 3.199

10.  High-Intensity Versus Low-Intensity Surveillance for Patients With Colorectal Adenomas: A Cost-Effectiveness Analysis.

Authors:  Reinier G S Meester; Iris Lansdorp-Vogelaar; Sidney J Winawer; Ann G Zauber; Amy B Knudsen; Uri Ladabaum
Journal:  Ann Intern Med       Date:  2019-09-24       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.